Anchor Capital Advisors LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Anchor Capital Advisors LLC reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 111,902 shares of the medical research company's stock after selling 7,372 shares during the quarter. Anchor Capital Advisors LLC owned 0.22% of Charles River Laboratories International worth $26,454,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Charles River Laboratories International by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company's stock valued at $1,166,837,000 after acquiring an additional 29,482 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Charles River Laboratories International by 3.9% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company's stock worth $342,201,000 after buying an additional 64,981 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,195,226 shares of the medical research company's stock worth $234,241,000 after purchasing an additional 6,398 shares in the last quarter. Ariel Investments LLC grew its position in Charles River Laboratories International by 1.8% during the third quarter. Ariel Investments LLC now owns 1,066,600 shares of the medical research company's stock worth $209,032,000 after buying an additional 18,760 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Charles River Laboratories International by 8.9% in the 3rd quarter. Invesco Ltd. now owns 927,895 shares of the medical research company's stock worth $181,849,000 after acquiring an additional 75,978 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, VP William D. Barbo sold 4,050 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares of the company's stock, valued at $5,685,431.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares of the company's stock, valued at $3,437,635. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last 90 days. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 1.3 %

NYSE CRL traded up $3.07 on Monday, reaching $232.10. The company had a trading volume of 322,958 shares, compared to its average volume of 548,434. The stock's 50 day moving average is $253.22 and its 200-day moving average is $223.32. The stock has a market cap of $11.96 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 1.79 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International's revenue for the quarter was down 7.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.98 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CRL shares. Robert W. Baird lifted their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. Citigroup increased their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. Evercore ISI boosted their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. Finally, TheStreet upgraded Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).